News & Events

Press Releases

Feb 07

Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy

- Company expediting planned dose escalation activities - - Low levels of SGT-001 microdystrophin protein detected at the starting dose - - Conference call to be held at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences (Nasdaq: SLDB) announced today

Read More
Jan 02

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot , Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th at 7:30 am

Read More